Community curated by people like you

Gilead Sciences stories

Oct 19, 2026

Gilead's emvistegrast eliminates symptoms in ulcerative colitis Phase 2 trial

Gilead Sciences reported mid-stage study results showing its oral α4β7 inhibitor emvistegrast eliminated symptoms in patients with ulcerative colitis, with remission rates exceeding those of Entyvio. The company plans to begin late-stage trials in 2027.

Oct 19, 2026·2 sources

00

Top claims

▪Gilead Sciences' emvistegrast is an oral α4β7 inhibitor developed to eliminate symptoms in patients with ulcerative colitis.
▪In a Phase 2 trial reported on October 19, 2026, a 200-milligram daily dose of Gilead Sciences' emvistegrast taken for 12 weeks achieved a 23% placebo-adjusted clinical remission rate in moderate to severe ulcerative colitis patients.
▪The Phase 2 clinical trial results for Gilead Sciences' emvistegrast demonstrated statistically significant improvement in ulcerative colitis symptoms that exceeded Wall Street analyst expectations.

Topics

Biologic therapies Clinical trials